Hyundai Pharm (004310) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Hyundai Pharm KRW 1,510, price KRW 8,860, upside -83.0%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Stretched ValuationStrong overvaluation with only moderate quality.
!Fair value 1,510 KRW · Strongly overvalued (−83%)
!Quality 58/100
!Mixed Growth(revenue 5y +7.6 %/yr)
!Thin margins · 1.3% net margin (TTM)
!Low debt · negative free cash flow
·0.34% dividend yield
!Mixed vs. peers(4/10)
!Narrow moat20/100
!Evidence only low, so the estimate is less certain
Watch Hyundai Pharm for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 2,992 KRW – 14,300 KRW · fair‑value band 1,057 KRW – 1,730 KRW · the 8,860 KRW price screens above the 1,510 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Hyundai Pharm in your weekly email
Every Wednesday you see whether Hyundai Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally.
Show more
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. Hyundai Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Seoul, South Korea.
Stock analysis
Hyundai Pharm (004310) currently trades at 8,860 KRW, while our model-based Fair Value estimate is 1,510 KRW, implying the stock looks roughly 486.5% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 1,779 KRW per share, and 0 of the 15 models we run sit above the 8,860 KRW price.
Bear case: the Earnings-Based group reads lowest at 422.41 KRW, and 15 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: 1,057 KRW (bear) to 1,730 KRW (bull), the price of 8,860 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Hyundai Pharm reported revenue of 192B KRW in FY2025 versus 140B KRW in FY2021, a compound +8.2%/yr. Reported net income was 2.5B KRW in FY2025.
Key figures
Market cap 232B KRW (≈ $170M) · P/S ratio 1.83 · Dividend yield 0.3% · Net margin 1.3% · Return on equity 1.5% · Return on assets (EBIT) 2.1% · Operating margin 1.7% · Revenue (TTM) 108B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 38% below its 52-week high and 151% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −83%, 004310 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (422.41 KRW to 3,720 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 1,057 KRWFair Value 1,510 KRWBull 1,730 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
’12
’13
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.7%
Dividend (yield on the price)0.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 2%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−83% · Bottom 25%
Profitability
Return on equity (TTM)1% · Below median
Return on assets1% · Below median
Net margin (TTM)1% · Below median
Operating margin (TTM)2% · Below median
Growth and dividend
Revenue growth5% · Above median
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
EV/EBITDA0.8× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)25· sector 20
PAST (return on equity)6· sector 27
HEALTH (low debt)97· sector 96
DIVIDEND (yield)7· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hyundai Pharm Fair Value". https://www.fairvalue-calculator.com/stock/004310
Frequently asked questions
Is Hyundai Pharm (004310) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,510 KRW versus a price of 8,860 KRW, about −83% upside (overvalued).
What is the fair value of 004310?
Our model-based fair value for Hyundai Pharm is 1,510 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 8,860 KRW.
What is the quality score of 004310?
Hyundai Pharm has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hyundai Pharm (004310)?
Our model-based price target is the fair value of 1,510 KRW (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 1,057 KRW, optimistic scenario 1,730 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Hyundai Pharm stock forecast for 2026?
Our models put fair value at 1,510 KRW, about −83% upside versus a price of 8,860 KRW (overvalued). Cautious scenario 1,057 KRW, optimistic scenario 1,730 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Hyundai Pharm (004310)?
Hyundai Pharm reported trailing-twelve-month revenue of about 108B KRW (latest available figure, as of Sep 24, 2026).
Does Hyundai Pharm pay a dividend?
Hyundai Pharm currently shows a dividend yield of about 0.34% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Hyundai Pharm (004310)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hyundai Pharm it is 1,510 KRW per share (as of Sep 24, 2026), against a price of 8,860 KRW. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Hyundai Pharm stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 004310 trades above its calculated fair value: price 8,860 KRW, fair value 1,510 KRW, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 004310?
No. The price is what the market pays today (8,860 KRW); the fair value is what the company's own numbers justify (1,510 KRW). For Hyundai Pharm the two are 7,350 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Hyundai Pharm worth?
The market values Hyundai Pharm at about 232B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 8,860 KRW; our models calculate a fair value of 1,510 KRW per share.
What do the bullish and bearish scenarios say about 004310?
Our models span a range for Hyundai Pharm: cautious scenario 1,057 KRW, base 1,510 KRW, optimistic 1,730 KRW per share (as of Sep 24, 2026, price 8,860 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hyundai Pharm (004310)?
Balance-sheet figures for Hyundai Pharm (as of Sep 24, 2026): return on equity 1.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 004310 from its 52-week high?
Hyundai Pharm trades at 8,860 KRW, about 38% below its 52-week high of 14,300 KRW and 151% above the low of 3,535 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,510 KRW is for.
Which stocks are comparable to Hyundai Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hyundai Pharm stock attractive at the current price?
The data as of Sep 24, 2026: price 8,860 KRW, calculated fair value 1,510 KRW (−83%), Quality Score 58/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 004310 calculated?
We run Hyundai Pharm through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,510 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Hyundai Pharm itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hyundai Pharm (004310)?
The closing price on Sep 23, 2026 was 8,860 KRW. Our model-based fair value is 1,510 KRW, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hyundai Pharm right now?
The price sits above even our optimistic bull case (1,730 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Hyundai Pharm
How large is the market capitalisation of Hyundai Pharm (004310)?
The market capitalisation of Hyundai Pharm is 232B KRW (≈ $170M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hyundai Pharm (004310)?
The price-to-sales ratio of Hyundai Pharm is 1.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Hyundai Pharm (004310)?
The dividend yield of Hyundai Pharm is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hyundai Pharm (004310)?
The net margin of Hyundai Pharm is 1.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hyundai Pharm (004310)?
The return on equity (ROE) of Hyundai Pharm is 1.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hyundai Pharm (004310)?
On an EBIT basis the return on assets of Hyundai Pharm is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hyundai Pharm (004310)?
The operating margin of Hyundai Pharm is 1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hyundai Pharm (004310)?
Revenue at Hyundai Pharm is growing +5.0% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hyundai Pharm (004310) generate?
The free cash flow of Hyundai Pharm is −6.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hyundai Pharm (004310) carry?
The net debt of Hyundai Pharm is 47.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hyundai Pharm in the live analysis
One click puts Hyundai Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
